Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Research & Development (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Research & Development data on record, last reported at $3.8 million in Q4 2025.

  • For Q4 2025, Research & Development fell 16.95% year-over-year to $3.8 million; the TTM value through Dec 2025 reached $17.4 million, down 9.46%, while the annual FY2025 figure was $17.4 million, 9.46% down from the prior year.
  • Research & Development reached $3.8 million in Q4 2025 per MRVI's latest filing, down from $3.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $9.2 million in Q4 2021 and bottomed at $1.9 million in Q2 2021.
  • Average Research & Development over 5 years is $4.4 million, with a median of $4.5 million recorded in 2023.
  • Peak YoY movement for Research & Development: skyrocketed 338.48% in 2021, then plummeted 45.37% in 2022.
  • A 5-year view of Research & Development shows it stood at $9.2 million in 2021, then tumbled by 45.37% to $5.0 million in 2022, then dropped by 8.32% to $4.6 million in 2023, then fell by 0.72% to $4.6 million in 2024, then dropped by 16.95% to $3.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $3.8 million in Q4 2025, $3.8 million in Q3 2025, and $4.9 million in Q2 2025.